Deslanoside
Based on 1 Customer Validation
Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations .
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.71%
- CAS No.: 17598-65-1
- Formule: C47H74O19
- Masse moléculaire:943.08
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Metabolism/Protease Compound Library
HY-L012
-
Natural Product Library
HY-L021
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Glycoside Compound Library
HY-L042
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Drug Metabolite Library
HY-L098
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Plant-Sourced Natural Product Library
HY-L115
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Withdrawn Drug Compound Library
HY-L140
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Mitochondrial Toxicity Compound Library
HY-L155
-
FDA-Approved Traditional Chinese Medicine Active Compound Library
HY-L163
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Natural Product Diversity Scaffold Library
HY-L245
-
Mass Spectrometry Natural Product Library
HY-L262
Activité biologique
Deslanoside (Desacetyllanatoside C) is a metabolite of Lanatoside C[4]. Deslanoside increases forearm blood flow and cardiac index and decreased heart rate concomitant with a marked decrease in skeletal muscle sympathetic nerve activity measured as an indicator of centrally mediated sympathetic nervous system activity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 17598-65-1
-
Appearance Solid
-
Masse moléculaire 943.08
-
Formule C47H74O19
-
Color White to off-white
-
SMILES
O[C@]([C@@](CC[C@@]1([H])[C@@]2(CC[C@H](O[C@@](O[C@H](C)[C@H]3O[C@@](O[C@H](C)[C@H]4O[C@@](O[C@H](C)[C@H]5O[C@]([C@@H]([C@@H](O)[C@@H]6O)O)([H])O[C@@H]6CO)([H])C[C@@H]5O)([H])C[C@@H]4O)([H])C[C@@H]3O)C1)C)([H])[C@]2([H])C[C@H]7O)(CC[C@@H]8C(CO9)=CC9=O)[C@]78C
-
Synonyms
Deacetyllanatoside C; Desacetyllanatoside C
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 100 mg/mL (106.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (2.21 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (2.21 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Hauptman PJ, et al. Digitalis. Circulation. 1999 Mar 9;99(9):1265-70. [Content Brief]
[2]. Wang L, et al. Ontology-based systematical representation and drug class effect analysis of package insert-reported adverse events associated with cardiovascular drugs used in China. Sci Rep. 2017 Oct 23;7(1):13819. [Content Brief]
[3]. Deslanoside.
[4]. Klys M, et al. Determination of deslanoside in antemortem and postmortem specimens. Unusual case report. Forensic Sci Int. 1990 Apr;45(3):231-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.0604 mL | 5.3018 mL | 10.6036 mL | 26.5089 mL |
| 5 mM | 0.2121 mL | 1.0604 mL | 2.1207 mL | 5.3018 mL | |
| 10 mM | 0.1060 mL | 0.5302 mL | 1.0604 mL | 2.6509 mL | |
| 15 mM | 0.0707 mL | 0.3535 mL | 0.7069 mL | 1.7673 mL | |
| 20 mM | 0.0530 mL | 0.2651 mL | 0.5302 mL | 1.3254 mL | |
| 25 mM | 0.0424 mL | 0.2121 mL | 0.4241 mL | 1.0604 mL | |
| 30 mM | 0.0353 mL | 0.1767 mL | 0.3535 mL | 0.8836 mL | |
| 40 mM | 0.0265 mL | 0.1325 mL | 0.2651 mL | 0.6627 mL | |
| 50 mM | 0.0212 mL | 0.1060 mL | 0.2121 mL | 0.5302 mL | |
| 60 mM | 0.0177 mL | 0.0884 mL | 0.1767 mL | 0.4418 mL | |
| 80 mM | 0.0133 mL | 0.0663 mL | 0.1325 mL | 0.3314 mL | |
| 100 mM | 0.0106 mL | 0.0530 mL | 0.1060 mL | 0.2651 mL |
Deslanoside Related Classifications
HY-A0154 Related Classifications
Powered by Bioz